Navigation Links
The 'Other' Cruciate Ligament: Newer Treatments for PCL Tears
Date:7/1/2009

New study reports on posterior cruciate ligament treatment options, but investigation is not over

ROSEMONT, Ill., July 1 /PRNewswire-USNewswire/ -- While major advances have been made in the understanding of posterior cruciate ligament (PCL) anatomy and reconstruction, a literature review published in the July 2009 issue of the Journal of the American Academy of Orthopaedic Surgeons (JAAOS) finds that there must be continued advances in basic science research in order to determine the best course of treatment for those with PCL injuries.

"An ACL (anterior cruciate ligament) tear is an injury of instability; a PCL tear is an injury of disability," said study author Matthew Matava, M.D., Associate Professor, Department of Orthopedic Surgery, Washington University School of Medicine, in Chesterfield, Missouri. "With a PCL injury, your knee won't buckle on you tomorrow, but in a few months or years it may become painful and not as strong or stable as it was prior to the injury. PCL tears are less frequently discussed because they are often left undiagnosed and the patient does not seek treatment for what they assumed was a mild injury."

PCL injuries are assessed by grades:

  • Grade 1: Partial tear (non-surgical treatment options recommended)
  • Grade 2: Isolated, near complete tear (non-surgical treatment options recommended)
  • Grade 3: Complete PCL torn, with other ligament injuries (surgery often recommended, but not always)

Two newer surgical options, along with one traditional method, are currently used to
'/>"/>

SOURCE American Academy of Orthopaedic Surgeons
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Another Reason Not to Smoke While Pregnant: Birth Defects
2. FDA Warns of Codeine Risk for Some Nursing Mothers
3. More than two-thirds of sexually active NYC youth use condoms, but other forms of birth control lag
4. One Species Genome Found Within Another
5. Claim Filed Against the Company and Nine Other Defendants in the Haifa Magistrates Court
6. Family-based treatment more effective than supportive psychotherapy in treating bulimia
7. Mother and Daughter Create Lead-Free/Safe Bibs and Solve Messy Mealtime Problems
8. Mothers Know Best: NFL Moms Team With Eddie George to Showcase a Better Way to a Healthier Lifestyle
9. Eat Seafood, See Weight Loss: Recent Study Finds Another Reason to Eat Seafood for a Fit Lifestyle
10. DTI Medical Corporation Announces Reverse Split and Other Corporate Developments
11. Chemotherapy may be culprit for fatigue in breast cancer survivors
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine News(10 mins):Health News:American Diversified Holdings Corporation Announces Stem Cell Patent Acquisition Program 2Health News:LodgeNet Interactive to Participate in UBS' 37th Annual Global Media and Communications Conference 2Health News:LodgeNet Interactive to Participate in UBS' 37th Annual Global Media and Communications Conference 3Health News:LodgeNet Interactive to Participate in UBS' 37th Annual Global Media and Communications Conference 4Health News:LodgeNet Interactive to Participate in UBS' 37th Annual Global Media and Communications Conference 5Health News:BHR Pharma Files Investigational New Drug Application, Receives Orphan Drug Designation, for Traumatic Brain Injury Treatment 2Health News:The Breema Center Presents a Yearlong Campaign to Transform Stress into Harmony in 2010 and Beyond 2Health News:LCA-Vision Joins Forces With the Wounded Warrior Project to Give the Gift of Enhanced Vision to Wounded American Heroes 2
Breaking Medicine Technology:Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease 2Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease 3Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease 4Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease 5Stallergenes: Oralair: Very Positive 3-Year Results of the Long-Term Study 2Stallergenes: Oralair: Very Positive 3-Year Results of the Long-Term Study 3Stallergenes: Oralair: Very Positive 3-Year Results of the Long-Term Study 4Stallergenes: Oralair: Very Positive 3-Year Results of the Long-Term Study 5Q-Med AB and Oceana Therapeutics, Inc. Take Major Step Towards SOLESTA(TM) US Regulatory Filing 2Q-Med AB and Oceana Therapeutics, Inc. Take Major Step Towards SOLESTA(TM) US Regulatory Filing 3Dendreon Announces Webcast Presentations at Upcoming Investor Conferences 13867 1Women Urged Not to Drink While Pregnant 56308 1Women Urged Not to Drink While Pregnant 56308 2Women Urged Not to Drink While Pregnant 56308 3Amgen to Present at the Baird Healthcare Conference 56306 1Amgen to Present at the Baird Healthcare Conference 56306 2